Cell Medica

Belkins
Cell Medica is a leading cellular immunotherapy company focused on the development, manufacturing and marketing of cell-based therapeutics for the treatment of cancer and the reconstitution of immune function.

Related News

INNATOSS LABORATORIES LAUNCHES NEUTRALIZING ANTIBODY TESTING SERVICE AGAINST SARS-COV-2 USING GENSCRIPT'S CPASS ™ KIT

Innatoss Laboratories | September 15, 2020

news image

Innatoss Laboratories announced today the first neutralizing antibody testing service against SARS-CoV-2 for the public in Europe, using GenScript's cPass ™ SARS-CoV-2 Neutralization Antibody Detection Kit. The kit is the first in the world that enables rapid detection of neutralizing antibodies (NAbs), the specific antibodies present in the serum of COVID-19 patients that are responsible for clearing the viral infection. Innatoss is the first medical lab in Europe to provide a service...

Read More

DIAGNOSTICS

MACROGENICS USES GENEDATA PROFILER TO IMPROVE IMMUNOTHERAPY DEVELOPMENT

MacroGenics, Genedata | April 20, 2021

news image

Genedata, the leading supplier of enterprise software solutions for biopharmaceutical R&D, revealed today a long-term collaboration agreement with MacroGenics, a biopharmaceutical firm and emerging pioneer in discovering and commercializing innovative immune-oncology therapeutics. The agreement provides MacroGenics access to Genedata Profiler® as well as consulting services to aid in the platform's accelerated adoption and integration into MacroGenics' R&D infrastructure.
Read More

AI

IKTOS PARTNERS WITH KADMON TO USE AI FOR NEW DRUG DESIGN

Iktos, Kadmon | May 19, 2021

news image

Iktos, a company specializing in Artificial Intelligence for new drug design, announced today that it has signed a Research Collaboration Agreement with Kadmon, a clinical-stage biopharmaceutical company based in New York, USA, under which Iktos' generative modeling artificial intelligence (AI) technology will be used to allow the rapid and cost-effective design of novel drug candidates. Iktos will use its de novo structure-based generative modeling technologies to find novel compounds that ...

Read More

BIOLINERX ANNOUNCES POSITIVE RESULTS FROM A PLANNED INTERIM ANALYSIS OF THE ONGOING GENESIS PHASE 3 TRIAL OF MOTIXAFORTIDE FOR STEM CELL MOBILIZATION

BioLineRx | October 30, 2020

news image

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a planned interim analysis of the ongoing GENESIS Phase 3 trial of motixafortide for stem cell mobilization (SCM) in multiple myeloma patients. At a meeting of the study's independent Data Monitoring Committee (DMC), a planned interim analysis of the study's primary endpoint was conducted independently by the DMC. Based on the statistically sig...

Read More

Innatoss Laboratories | September 15, 2020

news image

INNATOSS LABORATORIES LAUNCHES NEUTRALIZING ANTIBODY TESTING SERVICE AGAINST SARS-COV-2 USING GENSCRIPT'S CPASS ™ KIT

Innatoss Laboratories announced today the first neutralizing antibody testing service against SARS-CoV-2 for the public in Europe, using GenScript's cPass ™ SARS-CoV-2 Neutralization Antibody Detection Kit. The kit is the first in the world that enables rapid detection of neutralizing antibodies (NAbs), the specific antibodies present in the serum of COVID-19 patients that are responsible for clearing the viral infection. Innatoss is the first medical lab in Europe to provide a service...

Read More

DIAGNOSTICS

MacroGenics, Genedata | April 20, 2021

news image

MACROGENICS USES GENEDATA PROFILER TO IMPROVE IMMUNOTHERAPY DEVELOPMENT

Genedata, the leading supplier of enterprise software solutions for biopharmaceutical R&D, revealed today a long-term collaboration agreement with MacroGenics, a biopharmaceutical firm and emerging pioneer in discovering and commercializing innovative immune-oncology therapeutics. The agreement provides MacroGenics access to Genedata Profiler® as well as consulting services to aid in the platform's accelerated adoption and integration into MacroGenics' R&D infrastructure.
Read More

AI

Iktos, Kadmon | May 19, 2021

news image

IKTOS PARTNERS WITH KADMON TO USE AI FOR NEW DRUG DESIGN

Iktos, a company specializing in Artificial Intelligence for new drug design, announced today that it has signed a Research Collaboration Agreement with Kadmon, a clinical-stage biopharmaceutical company based in New York, USA, under which Iktos' generative modeling artificial intelligence (AI) technology will be used to allow the rapid and cost-effective design of novel drug candidates. Iktos will use its de novo structure-based generative modeling technologies to find novel compounds that ...

Read More

BioLineRx | October 30, 2020

news image

BIOLINERX ANNOUNCES POSITIVE RESULTS FROM A PLANNED INTERIM ANALYSIS OF THE ONGOING GENESIS PHASE 3 TRIAL OF MOTIXAFORTIDE FOR STEM CELL MOBILIZATION

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a planned interim analysis of the ongoing GENESIS Phase 3 trial of motixafortide for stem cell mobilization (SCM) in multiple myeloma patients. At a meeting of the study's independent Data Monitoring Committee (DMC), a planned interim analysis of the study's primary endpoint was conducted independently by the DMC. Based on the statistically sig...

Read More